Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XY4A
|
|||
| Former ID |
DIB005595
|
|||
| Drug Name |
BPS-804
|
|||
| Synonyms |
Anti-sclerostin antibody (osteoporosis/hypophophatasia), Novartis
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Metabolic bone disease [ICD-11: FB8Y] | Phase 2 | [1] | |
| Company |
Novartis AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sclerostin (SOST) | Target Info | . | [2] |
| KEGG Pathway | Wnt signaling pathway | |||
| NetPath Pathway | TWEAK Signaling Pathway | |||
| Reactome | TCF dependent signaling in response to WNT | |||
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01806610) Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease. U.S. National Institutes of Health. | |||
| REF 2 | WO patent application no. 2010,1001,79, Self-forming gel system for sustained drug delivery. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.